6K9 Stock Chart & Stats
€0.30
€0.03(5.70%)
At close: 4:00 PM EDT
€0.30
€0.03(5.70%)
Day’s Range― - ―
52-Week Range€0.25 - €3.12
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€28.70M
Enterprise Value€9.98
Total Cash (Recent Filing)€42.99M
Total Debt (Recent Filing)€244.99K
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Nov 11, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding91,879,170
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.76Price Target Upside820.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionA focused T-cell engager pipeline gives CNTX multiple opportunities to create value across solid-tumor indications. Progress in CTIM-76 and CT-202, combined with planned milestones through 2027, supports durable development optionality.
Clinical ValidationPositive early clinical data can improve the probability of advancing CTIM-76, attracting partners, and securing future funding. A stated runway into mid-2027 also provides time to generate additional data before major development decisions.
Low Financial LeverageMinimal debt limits interest obligations and reduces balance-sheet risk while CNTX funds clinical development. Although the company remains dependent on external capital, low leverage preserves flexibility compared with a similarly unprofitable biotech carrying substantial debt.
Bears Say
Pre-Revenue Business ModelCNTX has no commercial product revenue to offset research and operating costs, leaving financial performance dependent on clinical progress and fundraising. Widening losses increase the time and capital required to reach a sustainable commercial model.
Cash Burn And Equity ErosionHeavy and worsening cash consumption is eroding the capital base and raises the likelihood of additional financing before commercialization. Future equity issuance could dilute existing holders and may constrain development if funding conditions weaken.
Nasdaq Listing Compliance RiskThe minimum-bid deficiency creates a persistent listing risk that could complicate capital raising, reduce investor access, and require corporate actions to regain compliance. Failure to cure the issue within applicable windows could ultimately lead to delisting.
Context Therapeutics News
6K9 FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was €0.25 and its highest was €3.12 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is €28.70M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 66 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Aug 05, 2026. The company reported -€0.128 earnings per share for the quarter, missing the consensus estimate of -€0.079 by -€0.05.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 91,879,170 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -€0.128 in its last earnings report, missing expectations of -€0.079. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in DE:6K9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-47.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
6K9 Stock 12 Month Forecast
Average Price Target
€2.76
▲(820.64% Upside)